TY - JOUR
T1 - Expert Consensus on Surgical Management of Primary Diffuse Type 2-Dominant Chronic Rhinosinusitis
AU - Blauwblomme, Manon
AU - Georgalas, Christos
AU - Ahmed, Shahzada
AU - Alobid, Isam
AU - Battaglia, Paolo
AU - Castelnuovo, Paolo
AU - Constantinidis, Jannis
AU - Dallan, Iacopo
AU - Eeckels, Anne Sophie
AU - Ferrari, Marco
AU - Gevaert, Philippe
AU - Grayson, Jessica
AU - Harvey, Richard
AU - Herman, Philippe
AU - Konstantinidis, Iordanis
AU - Lubbe, Darlene
AU - Meco, Cem
AU - Palmer, James
AU - Patel, Zara M.
AU - Strzembosz, Agnieszka
AU - Verillaud, Benjamin
AU - Woodworth, Bradford A.
AU - Van Zele, Thibaut
N1 - Publisher Copyright:
© 2025 The Author(s). International Forum of Allergy & Rhinology published by Wiley Periodicals LLC on behalf of American Academy of Otolaryngic Allergy and American Rhinologic Society.
PY - 2025/3
Y1 - 2025/3
N2 - Background: Chronic rhinosinusitis (CRS) poses significant challenges in surgical management due to the lack of clear guidelines, particularly in type 2 CRS. This review focuses on surgical approaches for primary diffuse type 2-dominant CRS, emphasizing preoperative and intraoperative strategies. Methods: A consensus group, comprising experts from Europe, United Kingdom, Australia, South Africa, North and South America, was assembled. Using a modified Delphi method, 67 statements were formulated following a literature review, with an additional statement added in the second iteration. Final recommendations were discussed during a consensus meeting in Santorini, Greece, in October 2023. Results: Out of the 68 proposed statements, consensus was achieved on 45. Most (34) statements received a median score of 7 (strongly agree), and 11 had a median score of 6 (agree). The finalized recommendations cover the indications, timing, extent of surgery, and intraoperative management for both primary and revision surgery in primary diffuse type 2-dominant CRS. A key focus is on complete sinus surgery, which involves creating a neo-sinus cavity by removing bone partitions in the ethmoid and opening the frontal and sphenoidal sinuses as needed. Adequate primary and revision surgery includes clearing all nasal polyps and diseased mucosa while ensuring ideal conditions for topical therapy. Additionally, there was consensus on performing complete sinus surgery before considering monoclonal antibody therapies, unless contraindicated. Conclusion: These 45 consensus statements, derived from both current evidence and expert opinion, provide valuable guidance for clinicians in the surgical management of primary diffuse type 2-dominant CRS.
AB - Background: Chronic rhinosinusitis (CRS) poses significant challenges in surgical management due to the lack of clear guidelines, particularly in type 2 CRS. This review focuses on surgical approaches for primary diffuse type 2-dominant CRS, emphasizing preoperative and intraoperative strategies. Methods: A consensus group, comprising experts from Europe, United Kingdom, Australia, South Africa, North and South America, was assembled. Using a modified Delphi method, 67 statements were formulated following a literature review, with an additional statement added in the second iteration. Final recommendations were discussed during a consensus meeting in Santorini, Greece, in October 2023. Results: Out of the 68 proposed statements, consensus was achieved on 45. Most (34) statements received a median score of 7 (strongly agree), and 11 had a median score of 6 (agree). The finalized recommendations cover the indications, timing, extent of surgery, and intraoperative management for both primary and revision surgery in primary diffuse type 2-dominant CRS. A key focus is on complete sinus surgery, which involves creating a neo-sinus cavity by removing bone partitions in the ethmoid and opening the frontal and sphenoidal sinuses as needed. Adequate primary and revision surgery includes clearing all nasal polyps and diseased mucosa while ensuring ideal conditions for topical therapy. Additionally, there was consensus on performing complete sinus surgery before considering monoclonal antibody therapies, unless contraindicated. Conclusion: These 45 consensus statements, derived from both current evidence and expert opinion, provide valuable guidance for clinicians in the surgical management of primary diffuse type 2-dominant CRS.
KW - consensus statements
KW - Delphi method
KW - endoscopic sinus surgery
KW - extent of surgery
KW - nasal polyps
KW - revision surgery
UR - https://www.scopus.com/pages/publications/85217490278
U2 - 10.1002/alr.23538
DO - 10.1002/alr.23538
M3 - Review article
C2 - 39927867
AN - SCOPUS:85217490278
SN - 2042-6976
VL - 15
SP - 303
EP - 316
JO - International Forum of Allergy and Rhinology
JF - International Forum of Allergy and Rhinology
IS - 3
ER -